Supira Medical Announces Successful First-In-Human Use Of Its Next Generation Percutaneous Ventricular Assist Device

Three leading U.S. interventional cardiologists attend initial cases as company prepares to expand its clinical program

Los Gatos, Calif., September 16, 2022 – Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay. The prospective, single-arm, single-center study will evaluate the safety and performance of Supira’s low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).

Read More

Supira Medical Announces Successful First-In-Human Use Of Its Next Generation Percutaneous Ventricular Assist Device2022-09-15T15:43:10-07:00

Supira Medical, A Shifamed Portfolio Company, Closes $30m in an Oversubscribed Series C Financing

Company to Advance its Next Generation Percutaneous Ventricular Assist Device

Los Gatos, Calif., February 28, 2022 – Supira Medical, Inc., a Shifamed portfolio company that is focused on developing a next-generation solution for temporary mechanical circulatory support, announced today the closing of $30M in Series C financing. Led by Cormorant Asset Management and The Capital Partnership (TCP), with participation from 415 CAPITAL, AMED Ventures, PA MedTech VC Fund and Shifamed angel investors, the funds will be used to finalize product development and initiate a first-in-human clinical study for the company’s high-flow, low-profile percutaneous ventricular assist device (pVAD).

Read More

Supira Medical, A Shifamed Portfolio Company, Closes $30m in an Oversubscribed Series C Financing2022-02-25T15:55:43-08:00

Supira Medical, A Shifamed Portfolio Company, Closes $35M in Series B Financing

Company Appoints Seasoned Medtech Executive as President and CEO

CAMPBELL, Calif., March 5, 2020 – Supira Medical, formed by Shifamed as part of its medical innovation hub, announced today the closing of $35M in Series B financing. Officially closed on February 25, the financing was led by Cormorant Asset Management with participation from The Capital Partnership (TCP), 415 CAPITAL, AMED Ventures and Shifamed Angels. The funds will be used to advance product development and clinical efforts for the company’s next generation percutaneous ventricular assist device (pVAD). Additionally, the company announced the appointment of seasoned medical device executive, Dr. Nitin Salunke, as President and Chief Executive Officer.

Read More

Supira Medical, A Shifamed Portfolio Company, Closes $35M in Series B Financing2020-04-17T11:43:44-07:00

1. Company Data on File
2. Cardiac Interventions Today, Jan/Feb 2018.

Supira, Supira Medical, the Supira logo, and all product and service names on this site are trademarks of Supira Medical, Inc. unless otherwise noted. No use is permitted without prior written authorization.
Currently in the research and development phase and is not available for sale in any country. © 2022 Supira Medical, Inc. All rights reserved.

Go to Top